GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. (5th November 2018)
- Record Type:
- Journal Article
- Title:
- GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. (5th November 2018)
- Main Title:
- GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA
- Authors:
- Diplas, Bill
Waitkus, Matthew
He, Xujun
Brosnan-Cashman, Jackie
Liu, Heng
Chen, Lee
Wang, Zhaohui
Moure, Casey
Killela, Patrick
Lipp, Eric
Rodriguez, Fausto
Jiao, Yuchen
McLendon, Roger
Bigner, Darell
Meeker, Alan
Yan, Hai - Abstract:
- Abstract: Glioblastoma (GBM) is the most common and deadly primary malignant brain tumor in adults. Mutations in the TERT promoter ( TERTp ) and isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) can classify ~80% of GBMs into molecular subgroups with distinct clinical courses. These molecular subgroups utilize distinct genetic mechanisms of telomere maintenance, either TERTp mutation leading to telomerase activation or ATRX -mutation leading to an alternative lengthening of telomeres phenotype (ALT). However, approximately 20% of GBMs lack alterations in TERTp and IDH1/2 . These tumors, designated TERTp WT - IDH WT or triple-negative glioblastomas (as they also lack 1p19q co-deletion) do not have well-established genetic biomarkers or defined mechanisms of telomere maintenance. Here we performed whole-exome, whole-genome, and RNA-sequencing on a cohort of triple-negative GBMs to define their genetic landscape. We discovered recurrent inactivating mutations in SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A-like 1 ( SMARCAL1 ) in 21% (8/39) of triple-negative GBMs. Using telomere maintenance characterization assays, we show that SMARCAL1 -mutant cases exhibited the ALT phenotype. Using CRISPR/Cas9 gene editing in GBM cell lines, we found that inducing loss of SMARCAL1 generates features of ALT. Rescue of expression of SMARCAL1 in SMARCAL1 -null cell lines markedly suppressed ALT features and was dependent on the enzyme helicase activity.Abstract: Glioblastoma (GBM) is the most common and deadly primary malignant brain tumor in adults. Mutations in the TERT promoter ( TERTp ) and isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) can classify ~80% of GBMs into molecular subgroups with distinct clinical courses. These molecular subgroups utilize distinct genetic mechanisms of telomere maintenance, either TERTp mutation leading to telomerase activation or ATRX -mutation leading to an alternative lengthening of telomeres phenotype (ALT). However, approximately 20% of GBMs lack alterations in TERTp and IDH1/2 . These tumors, designated TERTp WT - IDH WT or triple-negative glioblastomas (as they also lack 1p19q co-deletion) do not have well-established genetic biomarkers or defined mechanisms of telomere maintenance. Here we performed whole-exome, whole-genome, and RNA-sequencing on a cohort of triple-negative GBMs to define their genetic landscape. We discovered recurrent inactivating mutations in SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A-like 1 ( SMARCAL1 ) in 21% (8/39) of triple-negative GBMs. Using telomere maintenance characterization assays, we show that SMARCAL1 -mutant cases exhibited the ALT phenotype. Using CRISPR/Cas9 gene editing in GBM cell lines, we found that inducing loss of SMARCAL1 generates features of ALT. Rescue of expression of SMARCAL1 in SMARCAL1 -null cell lines markedly suppressed ALT features and was dependent on the enzyme helicase activity. Furthermore, using break-apart FISH and whole genome sequencing, we identified recurrent rearrangements upstream of TERT in ~50% of triple-negative GBMs. These TERT -rearranged tumors exhibited elevated levels of TERT mRNA expression. This represents a novel mechanism of telomerase activation in GBMs lacking the well-known TERT promoter hotspot mutations. Finally, we identify recurrent BRAF V600E mutations in younger patients with GBM. Collectively, our findings define novel molecular subgroups of glioblastoma, including a telomerase-positive subgroup driven by TERT -structural rearrangements ( IDH WT - TERT SV, ~50%), and an ALT-positive subgroup ( IDH WT -ALT, ~40%) with mutations in ATRX or SMARCAL1. We also establish SMARCAL1 inactivating … (more)
- Is Part Of:
- Neuro-oncology. Volume 20(2018)Supplement 6
- Journal:
- Neuro-oncology
- Issue:
- Volume 20(2018)Supplement 6
- Issue Display:
- Volume 20, Issue 6 (2018)
- Year:
- 2018
- Volume:
- 20
- Issue:
- 6
- Issue Sort Value:
- 2018-0020-0006-0000
- Page Start:
- vi112
- Page End:
- vi112
- Publication Date:
- 2018-11-05
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noy148.468 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12325.xml